ABOS
Price
$1.93
Change
+$0.18 (+10.29%)
Updated
Dec 3 closing price
Capitalization
116.91M
116 days until earnings call
Intraday BUY SELL Signals
SKYE
Price
$1.22
Change
+$0.11 (+9.91%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
38.95M
Intraday BUY SELL Signals
Interact to see
Advertisement

ABOS vs SKYE

Header iconABOS vs SKYE Comparison
Open Charts ABOS vs SKYEBanner chart's image
Acumen Pharmaceuticals
Price$1.93
Change+$0.18 (+10.29%)
Volume$136.21K
Capitalization116.91M
Skye Bioscience
Price$1.22
Change+$0.11 (+9.91%)
Volume$700
Capitalization38.95M
ABOS vs SKYE Comparison Chart in %
ABOS
Daily Signal:
Gain/Loss:
SKYE
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ABOS vs. SKYE commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a StrongBuy and SKYE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (ABOS: $1.76 vs. SKYE: $1.12)
Brand notoriety: ABOS and SKYE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 26% vs. SKYE: 32%
Market capitalization -- ABOS: $115.7M vs. SKYE: $38.95M
ABOS [@Biotechnology] is valued at $115.7M. SKYE’s [@Biotechnology] market capitalization is $38.95M. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 0 FA rating(s) are green whileSKYE’s FA Score has 0 green FA rating(s).

  • ABOS’s FA Score: 0 green, 5 red.
  • SKYE’s FA Score: 0 green, 5 red.
According to our system of comparison, ABOS is a better buy in the long-term than SKYE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 6 TA indicator(s) are bullish while SKYE’s TA Score has 4 bullish TA indicator(s).

  • ABOS’s TA Score: 6 bullish, 4 bearish.
  • SKYE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ABOS is a better buy in the short-term than SKYE.

Price Growth

ABOS (@Biotechnology) experienced а -9.02% price change this week, while SKYE (@Biotechnology) price change was -12.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

ABOS is expected to report earnings on Mar 30, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABOS($117M) has a higher market cap than SKYE($38.9M). ABOS YTD gains are higher at: 2.616 vs. SKYE (-60.424). SKYE has higher annual earnings (EBITDA): -41.68M vs. ABOS (-132.35M). ABOS has more cash in the bank: 143M vs. SKYE (48.6M). SKYE has less debt than ABOS: SKYE (368K) vs ABOS (30.1M). ABOS (0) and SKYE (0) have equivalent revenues.
ABOSSKYEABOS / SKYE
Capitalization117M38.9M301%
EBITDA-132.35M-41.68M318%
Gain YTD2.616-60.424-4%
P/E RatioN/A3.57-
Revenue00-
Total Cash143M48.6M294%
Total Debt30.1M368K8,179%
FUNDAMENTALS RATINGS
SKYE: Fundamental Ratings
SKYE
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
93
P/E GROWTH RATING
1..100
97
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABOSSKYE
RSI
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 6 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 6 days ago
85%
Bullish Trend 6 days ago
87%
Momentum
ODDS (%)
Bullish Trend 6 days ago
82%
Bearish Trend 6 days ago
90%
MACD
ODDS (%)
Bullish Trend 6 days ago
84%
N/A
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
82%
Bullish Trend 6 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 6 days ago
85%
Bearish Trend 6 days ago
90%
Advances
ODDS (%)
Bullish Trend 8 days ago
79%
Bullish Trend 22 days ago
87%
Declines
ODDS (%)
Bearish Trend 17 days ago
87%
Bearish Trend 13 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 6 days ago
77%
Bullish Trend 6 days ago
89%
Aroon
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ABOS
Daily Signal:
Gain/Loss:
SKYE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TDOC7.520.08
+1.08%
Teladoc Health
PRIM124.621.16
+0.94%
Primoris Services Corp
INLX8.560.05
+0.59%
Intellinetics
GS815.464.60
+0.57%
Goldman Sachs Group
CIX21.87-0.62
-2.76%
Comp X International

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with BEAM. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
-7.11%
BEAM - ABOS
44%
Loosely correlated
-2.83%
CELC - ABOS
44%
Loosely correlated
-1.01%
SYRE - ABOS
42%
Loosely correlated
-0.91%
CRBU - ABOS
41%
Loosely correlated
-0.56%
CRSP - ABOS
40%
Loosely correlated
-1.13%
More

SKYE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SKYE has been loosely correlated with JANX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if SKYE jumps, then JANX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SKYE
1D Price
Change %
SKYE100%
-7.44%
JANX - SKYE
40%
Loosely correlated
-53.46%
NEVPF - SKYE
35%
Loosely correlated
N/A
VKTX - SKYE
34%
Loosely correlated
-2.00%
ABOS - SKYE
30%
Poorly correlated
-7.11%
RCKT - SKYE
30%
Poorly correlated
-2.06%
More